期刊文献+

慢性心力衰竭药物治疗研究进展 被引量:45

Research Progress on Pharmacological Therapy for Chronic Heart Failure
下载PDF
导出
摘要 慢性心力衰竭是诸多心血管疾病的最后阶段,难以逆转,一直是医学界面临的重大难题。慢性心力衰竭的治疗由过去强调改善症状、提升生活质量转变为以防治和延缓心肌重构为主,降低病死率和再住院率。现根据心力衰竭治疗指南和大型研究结果,对治疗慢性心力衰竭的常规药物、新药和中药的研究进展进行综述。 Chronic heart failure is the final phase of many cardiovascular diseases .It is difficult to reverse and has been the major problem facing the medicine filed .The focus of its treatment was changed from symptom remission and life quality improvement in the past into the deferring of myocardial remodeling , in order to reduce mortality and readmission rate .Based on guidelines and the results of large -scale researches , the study made a review of general drugs , new drugs and traditional Chinese medicine for chronic heart failure .
出处 《中国全科医学》 CAS CSCD 北大核心 2015年第23期2870-2872,共3页 Chinese General Practice
关键词 心力衰竭 醛固酮受体拮抗剂 伊伐布雷定 左西孟旦 抗凝药 LCZ696 综述 Heart failure Aldosterone antagonists Ivabradine Levosimendan Anticoagulants LCZ696 Review
  • 相关文献

参考文献19

  • 1中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122. 被引量:4689
  • 2Ferrario CM, Schiffrin EL. Role of mineralocorticoid receptor antagonists in cardiovascular disease [ J ]. Circ Res, 2015, 116 (1): 206-213.
  • 3Kim HY, Bae EH, Ma SK, et al. Effects of spironolactone in combination with Angiotensin- converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria [ J ]. Kidney Blood Press Res, 2014, 39 (6): 573-580.
  • 4Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators [ J]. N Engl J Med, 1999, 341 (10) : 709 -717.
  • 5Zannad F, Mcmurray JJ, Krum H, etal. Eplerenone in patients with systolic heart failure and mild symptoms [ J ]. N Engl J Med, 2011, 364 (1): 11-21.
  • 6Bisping E, Wakula P, Poteser M, et al. Targeting cardiac hypertrophy: toward a causal heart failure therapy [ J ]. J Cardiovasc Pharmacol, 2014, 64 (4): 293 - 305.
  • 7Tendera M, Talajic M, Robertson M, et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy ) [ J ]. Am J Cardiol, 2011, 107 (6): 805-811.
  • 8Swedberg K, Komajda M, Bahm M, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta - blocker dose?: findings from the SHIFT [ Systolic Heart failure treatment with the I (f) inhibitor ivabradine Trial]study [J]. J Am Coll Cardiol, 2012, 59 (22) : 1938 - 1945.
  • 9Follath F, Cleland JG, Just H, etal. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low - output heart failure ( the LIDO study) : a randomised double - blind tria[J]. Lancet, 2002, 360 (9328): 196 - 202.
  • 10van Hees HW, Dekhuijzen PN, Heunks LM. Levosimendan enhances force generation of diaphragm muscle from patients with chronic obstructive pulmonary disease [J]. Am J Respir Crit Care Med, 2009, 179 (1): 41-47.

二级参考文献12

共引文献4730

同被引文献372

引证文献45

二级引证文献324

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部